(American Journal of Pathology. 1999;154:1877-1881.)
© 1999 American Society for Investigative Pathology
Histological Damage in Chronic Hepatitis C Is Not Related to the Extent of Infection in the Liver
Elena Rodríguez-Iñigo*,
Javier Bartolomé*,
Susana de Lucas*,
Felix Manzarbeitia
,
Margarita Pardo*,
Carlos Arocena*,
Jaime Gosálvez
,
Horacio Oliva
and
Vicente Carreño*
From the Department of Hepatology,*
Fundación
Jiménez Díaz and Fundación Estudio Hepatitis
Virales, the Department of Pathology,
Fundación Jiménez Diaz, and the Department of
Biology,
Science Faculty, Universidad
Autónoma de Madrid, Madrid, Spain
 |
Abstract
|
|---|
It has not been completely elucidated whether the liver injury
induced by the hepatitis C virus (HCV) is due to direct cytopathic
damage or to an immune-mediated response against HCV-infected
hepatocytes. In this work, we have determined the percentage of
HCV-infected hepatocytes, the histological activity
index, and the viremia levels in chronically HCV-infected
patients with different grades of liver injury to investigate any
possible correlation between them. For that purpose, liver
biopsies from 27 patients with HCV chronic hepatitis were analyzed by
in situ hybridization. This technique revealed that the
percentage of infected hepatocytes ranged from 0.04% to 83.6%.
Regarding the viremia levels, HCV RNA concentration ranged from
1.8 x 103 to 1.4 x 106 genome
copies/ml. A significant correlation (r = 0.54;
P = 0.003) between the percentage of infected
hepatocytes and the viremia levels was found. In contrast, no
correlation was observed between the percentage of HCV-infected
hepatocytes or the viremia levels and the histological activity index.
In conclusion, we have shown that the HCV viremia reflects the
extent of the infection in the liver and that the liver injury in
chronic HCV infection is not directly related to either the number of
infected hepatocytes or the serum HCV RNA
concentration.
 |
Introduction
|
|---|
Chronic hepatitis C virus (HCV) infection is characterized by a
wide spectrum of liver damage, ranging from minimal lesions to liver
cirrhosis. The pathogenesis of HCV-induced liver injury has been
attributed to either direct cytopathic damage1-3
or to an
immune-mediated injury against HCV-encoded proteins.4-5
In an attempt to clarify this issue, several authors have analyzed the
relation between serum HCV viremia or the viral load in the liver and
the stage of liver disease with contradictory
results.6-12
However, none of these articles analyzed the
relationship between the number of HCV-infected hepatocytes and the
liver damage, which may be a better way to study this point.
On the other hand, whether serum HCV viremia reflects the viral load in
liver is still controversial.10,13
These differences may
be due to the fact that the methods used to quantify the HCV-RNA levels
in liver depend on a prior extraction of the total RNA from the
hepatocytes so that the quantification of the viral load in the liver
will depend on the efficiency of the extraction procedure. In a
previous report,14
we demonstrated using non-isotopic
in situ hybridization and digital image analysis of the
hybridization signals that serum HCV viremia is related to the
percentage of infected hepatocytes in HCV-infected patients with
chronic active hepatitis.
In the present work we have determined the percentage of HCV-infected
hepatocytes in liver biopsies by in situ hybridization, the
histological activity index, and the serum viremia levels in
chronically HCV-infected patients with different grades of liver injury
in an attempt to reveal any possible correlation or interdependence
between them.
 |
Patients and Methods
|
|---|
Paraffin-embedded liver biopsies from 27 anti-HCV-positive and
serum HCV-RNA-positive patients (17 male, 10 female) with
histologically proven chronic hepatitis and abnormal alanine
aminotransferase (ALT) levels (mean, 174.88 ± 124.88 IU/L; range,
41538 IU/L) were analyzed by in situ hybridization. None
of the patients had hepatitis B surface antigen (HBsAg), anti-hepatitis
D virus antibodies (anti-HDV), or anti-hepatitis A virus IgM antibodies
(IgM anti-HAV). The histological diagnoses of the patients were minimal
chronic hepatitis with no fibrosis in 1 patient, mild chronic hepatitis
in 21 patients (2 with no fibrosis, 6 with mild fibrosis, 6 with
moderate fibrosis, 7 with severe fibrosis) and moderate chronic
hepatitis in 5 patients (1 with moderate fibrosis, 2 with severe
fibrosis, 2 with cirrhosis).
None of the patients was receiving antiviral or immunosuppressive
therapy when the liver biopsy was obtained. A serum sample obtained at
the same time as the liver biopsy and properly stored at -20°C was
available from each patient.
Viral Markers in Serum
HbsAg, anti-HDV, and IgM anti-HAV were tested by commercial enzyme
immunoassays (Abbott Laboratories, North Chicago, IL). Anti-HCV was
tested by a third-generation enzyme-linked immunosorbent assay test
(Ortho Diagnostic Systems, Raritan, NJ) and confirmed by
third-generation recombinant immunoblotting assay (RIBA III, Ortho).
HCV-RNA presence and levels were determined by using the Amplicor
Monitor Test Kit (HCV Monitor quantitative assay, Roche Diagnostic
Systems, Basel, Switzerland) following the instructions supplied by the
manufacturer.
HCV-RNA Genotyping
HCV-RNA genotyping in the patients was performed as described by
Navas et al.15
In Situ Hybridization
Paraffin-embedded liver sections of the patients were in
situ hybridized using a 340-bp cDNA corresponding to the 5'
noncoding region of the HCV genome as probe.
The in situ hybridization technique and the specific
controls used were performed as described by Gosálvez et
al.14
In the in situ hybridization experiments,
slides from two patients with chronic autoimmune hepatitis, two
patients with chronic hepatitis B, and six patients with chronic
alcoholic hepatitis, all of them without HCV markers, were used as
negative controls.
Image capture of in situ hybridized liver biopsies were
performed under a Leika DMB microscope. Images were acquired using a
CCD camera (DIC-N, World Precision Instruments, Cambridge, UK) and for
quantification of the infection low magnification (x20) objectives
were used. Single frames of each biopsy were used to construct a whole
liver biopsy using the Adobe Photoshop 4.0 software (Adobe Systems, San
Jose, CA). The areas of infection visualized with in situ
hybridization were localized by automatic segmentation protocols using
VISILOG 5.0 Image analysis software (NOESIS Vision, Inc., Quebec, PQ).
The percentage of infection in each patient was derived from the same
analyzed surface.
Histological Diagnosis
Two consecutive slides from each liver biopsy were stained with
hematoxylin-eosin for histological diagnosis. The histological activity
index was estimated according to Knodell et al16
and the
histological diagnosis made according to Desmet et al.17
The histological diagnoses were performed under code by two independent
pathologists.
Liver Function Test
Liver function tests were analyzed by standard methods
(SMAC-20, Technicon, New York, NY).
Statistical Analysis
The Spearman correlation was used for correlations. All
statistical analyses were performed using the SPSS package (release 6.0
for Windows, SPSS, Chicago, IL).
 |
Results
|
|---|
HCV-RNA in Serum
Genotyping of the HCV RNA isolated from serum and amplified by
reverse transcription-polymerase chain reaction revealed that all
patients were infected by the HCV 1b genotype.
With respect to serum viremia levels, the HCV RNA concentration in the
patients included in the study ranged from 1.8 x
103
to 1.4 x 106
genome copies/ml (Table 1)
.
View this table:
[in this window]
[in a new window]
|
Table 1. Percentage of HCV-Infected Hepatocytes, Serum Viremia Levels, and
Histological Activity Index (HAI) in the Patients Included in the Study
|
|
No statistical correlation was found between serum viremia levels and
the total histological activity index (r = 0.25,
P = 0.19) or its individual components: periportal
necrosis (r = 0.14, P = 0.47),
intralobular degeneration (r = 0.12,
P = 0.52), portal inflammation
(r = 0.31, P = 0.11), and
fibrosis (r = 0.28, P = 0.15).
Furthermore, no correlation was observed between the serum HCV-RNA
concentration and the biochemical liver function test, ALT
(r = 0.13, P = 0.48), aspartate
aminotransferase-AST (r = 0.22,
P = 0.26), and
glutamiltranspeptidase-GGTP
(r = 0.34, P = 0.08).
In Situ Hybridization
In situ hybridization using the HCV-derived probe
showed positive signals in the hepatocytes from the liver biopsies of
all anti-HCV-positive, serum HCV-RNA-positive patients analyzed.
Positive hepatocytes were randomly distributed throughout the liver
biopsies with no clustering in any specific part of the liver samples.
No hybridization signals were observed in other cell types within the
liver (Figure 1)
. Furthermore, no
positive signals were detected in the liver biopsies from the 10
anti-HCV-negative patients used as negative controls (Figure 1)
.

View larger version (141K):
[in this window]
[in a new window]
|
Figure 1. In situ hybridization and mapping of HCV virus in
different patients. a: negative control with no traces of
infected hepatocytes. Distribution of infected cells (arrow) in
patients with 1.8 x 104
genome copies/ml (b)
and with 1.2 x 106
genome copies/ml (c) in
serum. d: General view of a single frame capture to show the
distribution of the infection. e: Visualization of the
infection in a single hepatocyte.
|
|
Regarding the localization of the hybridization signals, there were
mainly detected in the cytoplasm of the hepatocytes, although nuclear
staining was also observed in scattered hepatocytes.
The percentage of infected hepatocytes ranged from 0.04% to 83.6%
(Table 1)
. A statistically significant correlation
(r = 0.54; P = 0.003) between
the percentage of infected hepatocytes and the serum viremia levels was
found (Figure 2)
.

View larger version (12K):
[in this window]
[in a new window]
|
Figure 2. Regression analysis of correlation between the percentage of infected
hepatocytes and the serum viral load (genome
copies/ml).
|
|
In contrast, no correlation was observed between the percentage of
HCV-infected hepatocytes and the histological activity index
(r = 0.08; P = 0.67) or its
individual components: periportal necrosis (r =
0.17, P = 0.38), intralobular degeneration
(r = -0.06, P = 0.75), portal
inflammation (r = 0.09, P =
0.62), and fibrosis (r = 0.116,
P = 0.56). Figure 3
shows
an example of two patients with different percentages of infected
hepatocytes and serum viremia levels but with similar histological
features. Furthermore, there is no correlation between the percentage
of infected hepatocytes and the ALT (r = -0.06,
P = 0.72), AST (r = -0.03,
P = 0.85), and GGTP (r = 0.068,
P = 0.73) levels.

View larger version (171K):
[in this window]
[in a new window]
|
Figure 3. Fibrous and inflammatory portal expansion in two cases of chronic
hepatitis C with very similar histological picture and different
percentage of infected hepatocytes and viral load in serum. The patient
in A had 1.8% infected hepatocytes and a viral load in serum
of 1.8 x 104
copies genome/ml in serum. The patient
in B had 41.6% infected hepatocytes and a viral load in serum
of 1.2 x 106
genome copies/ml. These two patients'
in situ hybridization results are shown in Figure 1, b and c
, respectively.
|
|
 |
Discussion
|
|---|
The liver pathogenesis of chronic HCV infection remains unclear.
It has been attributed to either a direct cytopathic effect of the
virus1-3
or to the host immune response against infected
hepatocytes.4,5
Several authors have tried to correlate
the viral load in the serum or liver with the degree of liver injury,
with conflicting results.6-12
Furthermore, whether the
viral load in the liver correlates with the serum viremia levels is
still in controversy.10,13
In the present study we have
used in situ hybridization to determine the number of
HCV-infected hepatocytes and we have correlated the results with the
individual components of the histological activity index and with the
serum viremia levels in patients with chronic HCV hepatitis.
We found that the serum viremia levels correlate with the percentage of
HCV-infected hepatocytes in patients whose liver damage ranged from
minimal hepatitis to liver cirrhosis. This finding confirms that the
serum HCV viremia reflects the extent of HCV infection in the
liver,14
and shows that this correlation does not
depend on the stage or grade of the liver injury. However, it should be
noted that the correlation between percentage of labeled hepatocytes
and serum viremia is not very strong. If the three patients with a high
level of viremia are removed from the analysis, then the difference in
percentage of labeled hepatocytes between high and low viremia is only
about twofold (48%), whereas viremia varies tenfold.
The correlation between viremia and percentage of infected hepatocytes
also suggests that HCV replication in extrahepatic tissues, such as
peripheral blood mononuclear cells18
or bone marrow
cells,19
does not significantly contribute to the HCV RNA
levels in serum.
On the other hand, we did not find any relation between the number of
HCV-infected hepatocytes and any of the parameters of the histological
activity index (periportal necrosis, intralobular degeneration, portal
inflammation, and fibrosis) described by Knodell et al.16
Furthermore, no correlation between the number of HCV-infected
hepatocytes and the liver function test (ALT, AST, and GGTP) was
observed. Considered as a whole, all these data suggest that HCV
infection of the hepatocytes does not per se contribute
significantly to the liver injury.
Our findings agree with previous reports in which the intrahepatic HCV
RNA concentration measured by different methods (dot blot polymerase
chain reaction or bDNA assay) was correlated with the liver
injury.11,12
However, a problem exists when methods that
depend on the extraction of the total RNA from the liver are used,
because serum contamination lead to an inadequate measurement of
intrahepatic HCV-RNA levels. In contrast, in situ
hybridization provides a direct measurement of the number of infected
hepatocytes and avoids this problem.
On the other hand, when the serum HCV RNA levels were correlated with
the components of the histological activity index and with the liver
enzyme levels, no correlation was found.
The data on the detection of HCV RNA in liver and in serum could imply
that the liver injury in the chronic HCV infection is not directly
related with the levels of viral replication and may be mediated by the
host immune response against HCV-infected hepatocytes. The fact that
there are HCV chronic carriers with normal or nearly normal liver
histology20
supports this hypothesis.
It should be pointed out that all of the patients included in this
study were infected with the HCV 1b genotype and that the mechanism of
liver injury induced by other HCV genotypes could be different.
However, it has been shown that there are no differences in
histological damage between patients infected by different HCV
genotypes,11,21
indicating that the same mechanism of
liver damage is provoked by the different HCV genotypes.
In conclusion, in this report we have shown that the serum HCV viremia
reflects the extent of the infection in the liver and that the liver
injury in chronic HCV infection is not directly related to the number
of infected hepatocytes or to the HCV RNA concentration in serum.
 |
Acknowledgements
|
|---|
We thank Mercedes Casqueiro, Teresa Cuellar, Jose Luis Ramiro, and
Mario Fernández for their cooperation in this work.
 |
Footnotes
|
|---|
Address reprint requests to Dr. Vicente Carreño, Department of Hepatology, Fundación Jiménez Díaz, Avda Reyes Católicos 2, 28040, Madrid, Spain.
E. R. I. is recipient of a grant from the Fundación para el Estudio de las Hepatitis Virales. S. L. is a research fellow of the Fundación Conchita Rábago.
Accepted for publication February 19, 1999.
 |
References
|
|---|
-
Shindo M, Di Bisceglie AM, Biswas R, Mihalik K, Feinstone SM: Hepatitis C virus replication during acute infection in the chimpanzee. J Infect Dis 1992, 166:424-427[Medline]
-
Kato N, Yokosuka O, Hosoda K, Ito Y, Onto M, Omata M: Quantification of hepatitis C virus by competitive reverse transcription-polymerase chain reaction: increase of the virus in advanced liver disease. Hepatology 1993, 18:16-20[Medline]
-
Yuki N, Hayashi N, Kamada T: HCV viraemia and liver injury in symptom-free blood donors [letter]. Lancet 1993, 342:444[Medline]
-
Hu KQ, Yu CH, Vierling JM: Direct detection of circulating hepatitis C virus RNA using probes from the 5' untranslated region. J Clin Invest 1992, 89:2040-2045
-
Di Bisceglie AM, Hoofnagle JH, Krawczynski K: Changes in hepatitis C virus antigen in liver with antiviral therapy. Gastroenterology 1993, 105:858-862[Medline]
-
Lau JY, Davis GL, Kniffen J, Quian KP, Urdea MS, Chan CS, Mizokani M, Neuwald PD, Wilber JC: Significance of serum hepatitis C virus RNA levels in chronic hepatitis C. Lancet 1993, 341:1501-1504[Medline]
-
Hagiwara H, Hayashi N, Mita E, Naito M, Kasahara A, Fusamoto H, Kamada T: Quantitation of hepatitis C virus RNA in serum of asymptomatic blood donors and patients with type C chronic liver disease. Hepatology 1993, 17:545-550[Medline]
-
Naito M, Hayashi N, Hagiwara H, Hiramatsu N, Kashahara A, Fusamoto H, Kamada T: Serum hepatitis C virus RNA quantity and histological features of hepatitis C virus carriers with persistently normal ALT levels. Hepatology 1994, 19:871-875[Medline]
-
Gretch D, Corey L, Wilson J, dela Rosa C, Willson R, Carithers R, Jr, Busch M, Hart J, Sayers M, Han J: Assessment of hepatitis C virus RNA levels by quantitative competitive RNA polymerase chain reaction: high-titer viremia correlates with advanced stage of disease. J Infect Dis 1994, 169:1219-1225[Medline]
-
Coelho-Little E, Jeffers LJ, Bartholomew M, Reddy KR, Schiff ER, Dailey PJ: Correlation of HCV-RNA levels in serum and liver of patients with chronic hepatitis C [letter]. J Hepatol 1995, 22:248[Medline]
-
McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW: Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996, 23:676-687[Medline]
-
De Moliner L, Pontisso P, De Salvo GL, Cavaletto L, Chemello L, Alberti A: Serum and liver HCV-RNA levels in patients with chronic hepatitis C: correlation with clinical and histological features. Gut 1998, 42:856-860[Abstract/Free Full Text]
-
Terrault NA, Dailey PJ, Ferrell L, Collins ML, Wilber JC, Urdea MS, Bhandari BN, Wright TL: Hepatitis C virus: quantitation and distribution in liver. J Med Virol 1997, 51:217-224[Medline]
-
Gosálvez J, Rodríguez-Iñigo E, Ramiro-Díaz JL, Bartolomé J, Tomás JF, Oliva H, Carreño V: Relative quantification and mapping of hepatitis C virus by in situ hybridization and digital image analysis. Hepatology 1998, 27:1428-1434[Medline]
-
Navas S, Castillo I, Martín J, Quiroga JA, Bartolomé J, Carreño V: Concordance of hepatitis C virus typing methods based on restriction fragments length polymorphism analysis in 5' non-coding region and NS4 serotyping, but not in core PCR or in a line probe assay. J Clin Microbiol 1997, 21:317-321
-
Knodell RG, Ishak KG, Black WL, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435[Medline]
-
Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ: Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994, 19:1513-1520[Medline]
-
Moldvay J, Deny P, Pol S, Brechot C, Lamas E: Detection of hepatitis C virus RNA in peripheral blood mononuclear cells of infected patients by in situ hybridization. Blood 1994, 83:269-273[Abstract/Free Full Text]
-
Sansonno D, Iacobeli AR, Cornacchiulo V, Iodice G, Dammacco F: Detection of hepatitis C virus (HCV) proteins by immunofluorescence and HCV RNA genomic sequences by non-isotopic in situ hybridization in bone marrow and peripheral blood mononuclear cells of chronically HCV-infected patients. Clin Exp Immunol 1996, 103:414-421[Medline]
-
Hoofnagle JH: Hepatitis C: The clinical spectrum of disease. Hepatology 1997, 26(Suppl):15S-20S[Medline]
-
Yamada M, Kakumu S, Yoshioka K, Higashi Y, Tanaka K, Ishikawa T, Takayanagi M: Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994, 39:234-239[Medline]
This article has been cited by other articles:

|
 |

|
 |
 
J. Bartolome, J. M. Lopez-Alcorocho, I. Castillo, E. Rodriguez-Inigo, J. A. Quiroga, R. Palacios, and V. Carreno
Ultracentrifugation of Serum Samples Allows Detection of Hepatitis C Virus RNA in Patients with Occult Hepatitis C
J. Virol.,
July 15, 2007;
81(14):
7710 - 7715.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Pal, M. C. Shuhart, L. Thomassen, S. S. Emerson, T. Su, N. Feuerborn, J. Kae, and D. R. Gretch
Intrahepatic Hepatitis C Virus Replication Correlates with Chronic Hepatitis C Disease Severity In Vivo
J. Virol.,
March 1, 2006;
80(5):
2280 - 2290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Rodriguez-Inigo, J. M. Lopez-Alcorocho, J. Bartolome, N. Ortiz-Movilla, M. Pardo, and V. Carreno
Percentage of Hepatitis C Virus-Infected Hepatocytes Is a Better Predictor of Response Than Serum Viremia Levels
J. Mol. Diagn.,
October 1, 2005;
7(4):
535 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Nardacci, O. Lo Iacono, F. Ciccosanti, L. Falasca, M. Addesso, A. Amendola, G. Antonucci, A. Craxi, G. M. Fimia, V. Iadevaia, et al.
Transglutaminase Type II Plays a Protective Role in Hepatic Injury
Am. J. Pathol.,
April 1, 2003;
162(4):
1293 - 1303.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M. Lagging, C. E. Garcia, J. Westin, R. Wejstal, G. Norkrans, A. P. Dhillon, and M. Lindh
Comparison of Serum Hepatitis C Virus RNA and Core Antigen Concentrations and Determination of Whether Levels Are Associated with Liver Histology or Affected by Specimen Storage Time
J. Clin. Microbiol.,
November 1, 2002;
40(11):
4224 - 4229.
[Abstract]
[Full Text]
[PDF]
|
 |
|